Our Products

CardioVax's Products in the Pipeline

Our therapies target the immune system to treat cardiovascular disease – a new way of treating the condition compared to the medicines on the market today. CardioVax's technologies aim to increase the immune system's tolerance to oxidized-LDL (sometimes referred to as "bad cholesterol"). Oxidized-LDL plays a key role in the progression of atherosclerosis and can cause an inflammatory response. We have three ongoing product programs – an injectable vaccine, a mucosal vaccine, and an autologous cellular immunotherapy.

 

Injectable Vaccine

CardioVax has been developing an injectable vaccine to create an immune response that slows the progression of atherosclerosis. Early results showed as much as a 60% reduction in atherosclerosis in mice. CardioVax has been optimizing the formulation to be suitable for use in humans. The vaccine is being developed as an injection that would be given by a healthcare provider. Currently, our evidence is supportive that an initial dose followed by booster treatments will convey the desired immunity for an extended period of time.

 

The injectable vaccine is comprised of CardioVax's patented technology, which uses a peptide fragment of apoB-100 (a component of LDL) as the active ingredient that conveys protection against atherosclerosis. The active ingredient suppresses the pro-inflammatory immune response and restores tolerance to oxidized LDL.

 

Mucosal Vaccine

The mucosal vaccine is based on the same underlying technology as the injectable vaccine. This product could be administered either orally, nasally, or even sublingually. Initial experiments with the mucosal vaccine have shown a 30% reduction in atherosclerosis in mice.

 

The mucosal vaccine is a fusion protein containing an apoB-100 peptide fragment attached at a carrier protein that facilitates a mucosal immune response. Like the injectable vaccine, the formulation is currently undergoing preclinical optimization. CardioVax has patents pending on the mucosal vaccine technology in 8 countries and Europe.

 

Autologous Cellular Immunotherapy

CardioVax is also evaluating autologous cellular immunotherapies. Autologous cellular immunotherapy involves modifying the patient's own immune cells outside the body. Once the cells are modified, they are put back into the patient and convey protection against atherosclerosis. In 2010, a similar therapeutic approach to treat prostate cancer was approved by the FDA and is currently available to patients in the United States. This approach has been shown to be the most potent anti-inflammatory immunotherapeutic treatment method, demonstrating a 70% reduction in atherosclerosis in mice after just one infusion treatment.

 

There are several preclinical experiments showing a substantial immunity is conveyed when the subject's cells are removed from the body, altered by exposure to apoB-100, and then re-infused back into the body in mice. This approach represents a promising treatment for cardiovascular disease if it can be successfully translated for use in patients.

 

NEXT > Intellectual Property

 

CV Logo Footer

10100 Santa Monica Blvd., Suite 925

Los Angeles, CA 90067 United States

Tel.: 424. 263. 6364

pagend